Type 2 Diabetes MellitusPhase 2/3NCT01318070

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

A Phase 2/3 study testing Alogliptin and pioglitazone and Pioglitazone in people with Type 2 Diabetes Mellitus, run by Takeda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose. Read more about this study

Who is it for?: Ages 33 to 88 years
Conditions the study is for: Type 2 Diabetes Mellitus
What is being tested?: Alogliptin and pioglitazone and Pioglitazone
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 339 participants
Where: No sites listed yet
Study dates: Nov 2007to Oct 2008
Phase: Phase 2/3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 33 to 88 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Had been taking pioglitazone at a stable dose (15 mg/day or 30 mg/day) for at least 16 weeks prior to the start of the treatment period (Week 0).
Had glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 14 weeks after the start of the observation period (Week -2).
Had HbA1c difference within 10.0%* at 10 weeks after the start of the observation period (Week -6) and 14 weeks after the start of the observation period (Week -2) from 10 weeks after the start of the observation period (Week -6) (*rounded off to the first decimal place).
Was receiving specific diet and exercise (if any) therapies during the observation period.

Who cannot join

Had taken a diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period (Week 0).
Had a history or symptoms of cardiac failure.

About this study

Official title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.

Read the detailed description

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.

The present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to pioglitazone in type 2 diabetic patients with uncontrolled blood glucose despite treatment with pioglitazone as well as diet and exercise therapies.

Conditions: Type 2 Diabetes Mellitus
Being tested: Alogliptin and pioglitazone, Pioglitazone
Keywords: Diabetes Mellitus - Type2, Diabetes Mellitus, Drug Therapy
Medical subject headings: Diabetes Mellitus, Type 2, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Alogliptin and pioglitazoneDrug
Also called Alogliptin (SYR-322), Pioglitazone: Actos®
Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Alogliptin and pioglitazoneDrug
Also called Alogliptin (SYR-322), Pioglitazone: Actos®
Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
PioglitazoneDrug
Also called Pioglitazone: Actos®
Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.

Study groups in NCT01318070
Study group	Role	What they receive
Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD	Experimental	Not described Receives: Drug: Alogliptin and pioglitazone
Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD	Experimental	Not described Receives: Drug: Alogliptin and pioglitazone
Pioglitazone (15mg or 30mg ) QD	Active comparator	Not described Receives: Drug: Pioglitazone

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline in Glycosylated Hemoglobin (Week 12).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 12.

Secondary outcomes (8)

Change From Baseline in Glycosylated Hemoglobin (Week 2).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 2.
Change From Baseline in Glycosylated Hemoglobin (Week 4).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 4.
Change From Baseline in Glycosylated Hemoglobin (Week 8).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 8.
Change From Baseline in Fasting Plasma Glucose (Week 2).
The change between the value of fasting plasma glucose collected at week 2 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 2.
Change From Baseline in Fasting Plasma Glucose (Week 4).
The change between the value of fasting plasma glucose collected at week 4 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 4.
Change From Baseline in Fasting Plasma Glucose (Week 8).
The change between the value of fasting plasma glucose collected at week 8 and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 8.
Change From Baseline in Fasting Plasma Glucose (Week 12).
The change between the value of fasting plasma glucose collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
Measured: Baseline and Week 12.
Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and 2 hours after the start of the meal.
Measured: Baseline and Week 12.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Nov 2007Oct 2008

First posted18 Mar 2011 (estimated)
Study startNov 2007
Primary completionOct 2008
Study completionOct 2008

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
More trials run by TakedaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2/3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 339 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01318070
Sponsor's protocol ID: SYR-322/CCT-004
Other IDs: UMIN000001382, JapicCTI-080590, U1111-1118-4073
Status last verified: Feb 2012
First submitted: 16 Mar 2011
Last updated: 3 Feb 2012
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

Official record

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

All Type 2 Diabetes Mellitus trials

Study at a glance

From the registry record, last updated by the sponsor on 3 Feb 2012. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan
ClinicalTrials.gov ID: NCT01318070
Acronym / sponsor ID: SYR-322/CCT-004
Conditions: Type 2 Diabetes Mellitus
Keywords: Diabetes Mellitus - Type2, Diabetes Mellitus, Drug Therapy
Phase: Phase 2/3
Study type: Interventional
Recruitment status: Completed
Enrolment: 339 participants (actual)
Lead sponsor: TakedaIndustry (pharma, biotech, devices)
Study start: Nov 2007
Primary completion: Oct 2008 (actual)
Study completion: Oct 2008 (actual)
First posted: 18 Mar 2011 (estimated)
Results: Posted 6 Jul 2011

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.

Detailed description

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 3

Arm	Type	Receives
Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD	Experimental	Drug: Alogliptin and pioglitazone
Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD	Experimental	Drug: Alogliptin and pioglitazone
Pioglitazone (15mg or 30mg ) QD	Active comparator	Drug: Pioglitazone

Who may qualify

Ages: 33 to 88 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Had been taking pioglitazone at a stable dose (15 mg/day or 30 mg/day) for at least 16 weeks prior to the start of the treatment period (Week 0).
Had glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 14 weeks after the start of the observation period (Week -2).
Had HbA1c difference within 10.0%* at 10 weeks after the start of the observation period (Week -6) and 14 weeks after the start of the observation period (Week -2) from 10 weeks after the start of the observation period (Week -6) (*rounded off to the first decimal place).
Was receiving specific diet and exercise (if any) therapies during the observation period.

Key exclusion criteria (2 listed)

Had taken a diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period (Week 0).
Had a history or symptoms of cardiac failure.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Alogliptin and pioglitazoneAlso: Alogliptin (SYR-322), Pioglitazone: Actos®Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.	Drug	Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD
Alogliptin and pioglitazoneAlso: Alogliptin (SYR-322), Pioglitazone: Actos®Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.	Drug	Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD
PioglitazoneAlso: Pioglitazone: Actos®Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.	Drug	Pioglitazone (15mg or 30mg ) QD

Primary outcome

Change From Baseline in Glycosylated Hemoglobin (Week 12).
Time frame: Baseline and Week 12.
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.

8 secondary outcomes

Change From Baseline in Glycosylated Hemoglobin (Week 2).
Time frame: Baseline and Week 2.
Change From Baseline in Glycosylated Hemoglobin (Week 4).
Time frame: Baseline and Week 4.
Change From Baseline in Glycosylated Hemoglobin (Week 8).
Time frame: Baseline and Week 8.
Change From Baseline in Fasting Plasma Glucose (Week 2).
Time frame: Baseline and Week 2.
Change From Baseline in Fasting Plasma Glucose (Week 4).
Time frame: Baseline and Week 4.
Change From Baseline in Fasting Plasma Glucose (Week 8).
Time frame: Baseline and Week 8.
Change From Baseline in Fasting Plasma Glucose (Week 12).
Time frame: Baseline and Week 12.
Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
Time frame: Baseline and Week 12.

Results and safety

Results posted to the registry on 6 Jul 2011, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD	111	109
Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD	113	111
Pioglitazone 15 mg or 30 mg QD	115	108

Primary outcome: Change From Baseline in Glycosylated Hemoglobin (Week 12).

Time frame: Baseline and Week 12.. Mean (Standard Deviation). Unit: percentage of Glycosylated Hemoglobin

Measure	Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD n = 111	Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD n = 113	Pioglitazone 15 mg or 30 mg QD n = 115
Value	-0.91 (0.441)	-0.97 (0.517)	-0.19 (0.552)

Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD vs Pioglitazone 15 mg or 30 mg QD: Median Difference (Final Values): -0.717 (95% CI -0.848 to -0.586)
Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD vs Pioglitazone 15 mg or 30 mg QD: Mean Difference (Final Values): -0.773 (95% CI -0.913 to -0.634)

Population analysed: Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.

8 secondary outcomes are reported in the full results.

Adverse events

Time frame: Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug.. Other adverse events reported at 3% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD	1 of 111 (0.9%)	5 of 111 (4.5%)	Not reported
Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD	2 of 113 (1.8%)	17 of 113 (15%)	Not reported
Pioglitazone 15 mg or 30 mg QD	5 of 115 (4.3%)	13 of 115 (11.3%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2012.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Type 2 Diabetes Mellitus

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Professor, Diabetes and Endocrine Division, Department of Medicine study director

Kawasaki Medical School

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Alogliptin and pioglitazone and Pioglitazone in people with Type 2 Diabetes Mellitus, run by Takeda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Feb 2012. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Jul 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Glycosylated Hemoglobin (Week 12). (time frame: Baseline and Week 12.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01318070.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2012.